EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial

Jun Mori, Yasuhisa Ohata, Yasuko Fujisawa, Yukihito Sato, Sebastian Röhrich, Michael Højby Rasmussen iD, Rikke Beck Bang, Reiko Horikawa

Clinical Endocrinology · 2024

DOI: 10.1111/cen.15025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Jun Mori und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Human Growth Hormone, Dwarfism, Pituitary, Histidine, Mannitol. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Somapacitan is a long‐acting growth hormone (GH) derivative developed for the treatment of GH deficiency (GHD). This study evaluates the efficacy and tolerability of somapacitan in Japanese children with GHD after 104 weeks of treatment and after switch from daily GH.

Design

Subanalysis on Japanese patients from a randomised, open‐labelled, controlled parallel‐group phase 3 trial (REAL4, NCT03811535). Patients and Measurements Thirty treatment‐naïve patients were randomised 2:1 to somapacitan (0.16 mg/kg/week) or daily GH (0.034 mg/kg/day) up to Week 52, after which all patients received somapacitan. Height velocity (HV; cm/year) at Weeks 52 and 104 were the primary measurements. Additional assessments included HV SD score (SDS), height SDS, bone age, insulin‐like growth factor‐I (IGF‐I) SDS, and observer‐reported outcomes.

Results

At Week 52, observed mean HV was similar between treatment groups (10.3 vs. 9.8 cm/year for somapacitan and daily GH, respectively). Similar HVs between groups were also observed at Week 104: 7.4 cm/year after continuous somapacitan treatment (soma/soma) and 7.9 cm/year after 1‐year somapacitan treatment following switch from daily GH (switch). Other height‐related endpoints supported continuous growth. IGF‐I SDS increased in both groups with mean IGF‐I SDS within −2 and +2 during the study. Somapacitan was well tolerated, one mild injection site reaction was reported, with no reports of injection site pain. Patient preference questionnaires showed that most patients and their caregivers (90.9%) who switched treatment at Week 52 preferred once‐weekly somapacitan over daily GH treatment.

Conclusions

Somapacitan showed sustained efficacy in Japanese children with GHD over 104 weeks and for 52 weeks after switching from daily GH. Somapacitan was well tolerated and preferred over daily GH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneDwarfism, PituitaryHistidineMannitolPhenolChildHumansGrowth HormoneInsulin-Like Growth Factor IJapan

Stichwörter der Autor:innen

Japanclinical trialgrowth hormonegrowth hormone deficiencygrowth hormone replacement therapylong-acting growth hormonesomapacitan

Substanzen

somapacitanGrowth HormoneInsulin-Like Growth Factor IHuman Growth HormoneHistidineMannitolPhenol

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.
  • Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Rare Disease Group, Novo Nordisk Pharma Ltd., Tokyo, Japan.
  • Global Medical Affairs, Novo Nordisk Health Care AG, Zürich, Switzerland.
  • Medical and Science, Rare Disease and Advanced Therapies, Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark.

ORCID-Profile: Michael Højby Rasmussen

Förderung

  • Novo Nordisk

Zitieren

APA

Mori, J., Ohata, Y., Fujisawa, Y., Sato, Y., Röhrich, S., Rasmussen, M. H., Bang, R. B., & Horikawa, R. (2024). Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical Endocrinology. https://doi.org/10.1111/cen.15025

Vancouver

Mori J, Ohata Y, Fujisawa Y, Sato Y, Röhrich S, Rasmussen MH, et al. Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical Endocrinology. 2024. doi:10.1111/cen.15025

BibTeX
@article{Mori2024,
  author = {Mori, Jun and Ohata, Yasuhisa and Fujisawa, Yasuko and Sato, Yukihito and Röhrich, Sebastian and Rasmussen, Michael Højby and Bang, Rikke Beck and Horikawa, Reiko},
  title = {Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial},
  journal = {Clinical Endocrinology},
  year = {2024},
  doi = {10.1111/cen.15025}
}
Kostenlos starten →